Profile data is unavailable for this security.
About the company
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its contract research organization (CRO) independent product development platform to partner with other life science companies to develop and commercialize products in the United States. The Company’s clinical-stage oncology product candidate is TRC102, which is a small molecule that has been studied in Phase 1 and Phase 2 trials for the treatment of mesothelioma, lung cancer, glioblastoma and solid tumors and YH001, which is a monospecific investigational cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) antibody. TRC102 is a small molecule in clinical development to reverse resistance to specific chemotherapeutics by inhibiting DNA base excision repair (BER). Its clinical-stage product candidate, Envafolimab, is a PD-L1 antibody that is being developed for the treatment of sarcoma.
- Revenue in USD (TTM)3.20m
- Net income in USD5.20m
- Incorporated2004
- Employees17.00
- LocationTRACON Pharmaceuticals Inc4350 LA JOLLA VILLAGE DRIVE, SUITE 800SAN DIEGO 92122United StatesUSA
- Phone+1 (858) 550-0780
- Fax+1 (302) 636-5454
- Websitehttps://www.traconpharma.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Life Stem Genetics Inc | 0.00 | -568.02k | 393.34k | 1.00 | -- | 0.21 | -- | -- | -0.013 | -0.013 | 0.00 | 0.0076 | 0.00 | -- | -- | 0.00 | -198.83 | -- | -330.32 | -- | -- | -- | -- | -- | -- | -- | 0.0241 | -- | -- | -- | -- | -- | -- | -- |
| ITonis Inc | 0.00 | -1.17m | 609.36k | -- | -- | -- | -- | -- | -0.0012 | -0.0012 | 0.00 | -0.0004 | 0.00 | -- | -- | -- | -187.63 | -- | -1,169.36 | -- | -- | -- | -- | -- | -- | -0.8999 | -- | -- | -- | -- | -506.86 | -- | -- | -- |
| TRACON Pharmaceuticals Inc | 3.20m | 5.20m | 707.07k | 17.00 | 0.0547 | -- | 0.1357 | 0.221 | 3.79 | 3.79 | 1.39 | -0.9065 | 0.3267 | -- | -- | 188,235.30 | 53.04 | -79.42 | -- | -177.85 | -- | -- | 162.34 | -813.81 | -- | -19.35 | -- | -- | -- | 32.05 | 87.68 | -- | -- | -- |
| Resonate Blends Inc | 751.28k | -1.88m | 797.05k | 6.00 | -- | -- | -- | 1.06 | -0.0205 | -0.0205 | 0.0083 | -0.0244 | 0.632 | -- | 11.93 | -- | -158.40 | -680.29 | -- | -- | 46.92 | -78.88 | -250.64 | -12,895.26 | -- | -2.30 | 4.00 | -- | -66.73 | -56.57 | -316.63 | -- | -- | -- |
| PainReform Ltd | 0.00 | -17.67m | 881.21k | 6.00 | -- | -- | -- | -- | -41.92 | -41.92 | 0.00 | -3.53 | 0.00 | -- | -- | 0.00 | -309.43 | -55.47 | -650.22 | -68.20 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -6.28 | -- | -- | -- |
| Agentix Corp | 0.00 | -585.16k | 906.02k | -- | -- | -- | -- | -- | -0.0146 | -0.0146 | 0.00 | -0.0639 | 0.00 | -- | -- | -- | -318.23 | -- | -- | -- | -- | -- | -- | -- | -- | -19.24 | -- | -- | -- | -- | 57.41 | -- | -- | -- |
| Bespoke Extracts Inc | 956.86k | -1.36m | 966.01k | 10.00 | -- | -- | -- | 1.01 | -0.1331 | -0.1331 | 0.0941 | -0.194 | 2.29 | 20.10 | 21.36 | 95,686.00 | -325.13 | -- | -- | -- | 45.50 | -- | -141.75 | -- | 0.0482 | -53.38 | -- | -- | 22,933.72 | -- | 63.98 | -- | -- | -- |
| Evofem Biosciences Inc | 17.71m | 57.36m | 973.19k | 37.00 | 0.0007 | -- | 0.0169 | 0.0549 | -0.4918 | -0.4918 | 0.0297 | -0.7803 | 1.57 | 1.81 | 3.61 | 478,756.80 | 534.21 | -211.64 | -- | -- | 75.75 | -- | 341.16 | -1,031.55 | 0.0841 | -4.50 | -- | -- | 8.20 | -- | 164.08 | -- | -10.59 | -- |
| CanaQuest Medical Corp | 0.00 | -812.13k | 1.05m | -- | -- | -- | -- | -- | -0.0517 | -0.0517 | 0.00 | -0.0372 | 0.00 | -- | -- | -- | -1,084.38 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 57.42 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Game Plan Financial Advisors LLCas of 30 Jun 2024 | 50.00 | 0.00% |
| G1 Execution Services LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| SpiderRock Advisors LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Squarepoint OPS LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Geode Capital Management LLCas of 31 Jul 2024 | 0.00 | 0.00% |
| Abaris Investment Management AGas of 31 Dec 2023 | 0.00 | 0.00% |
| XTX Markets LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Truvestments Capital LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Jane Street Capital LLCas of 30 Jun 2024 | 0.00 | 0.00% |
| Cutler Group LLCas of 31 Mar 2024 | 0.00 | 0.00% |
